Xiidra FDA Approval History
FDA Approved: Yes (First approved July 11, 2016)
Brand name: Xiidra
Generic name: lifitegrast
Dosage form: Ophthalmic Solution
Company: Shire plc
Treatment for: Dry Eye Disease
Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease.
Development Timeline for Xiidra
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.